Published in Eur J Pharmacol on December 19, 1996
Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc Natl Acad Sci U S A (2000) 1.38
The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of post-traumatic stress disorder. Neuropsychopharmacology (2011) 1.21
The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice. Psychopharmacology (Berl) (2007) 1.14
Countervailing modulation of Ih by neuropeptide Y and corticotrophin-releasing factor in basolateral amygdala as a possible mechanism for their effects on stress-related behaviors. J Neurosci (2010) 1.02
Effect of pharmacological manipulations of neuropeptide Y and corticotropin-releasing factor neurotransmission on incubation of conditioned fear. Neuroscience (2009) 0.98
NPY Y1 receptors differentially modulate GABAA and NMDA receptors via divergent signal-transduction pathways to reduce excitability of amygdala neurons. Neuropsychopharmacology (2013) 0.85
Peripheral and central administration of a selective neuropeptide Y Y1 receptor antagonist suppresses ethanol intake by C57BL/6J mice. Alcohol Clin Exp Res (2004) 0.81
Delayed stress-induced differences in locomotor and depression-related behaviour in female neuropeptide-Y Y1 receptor knockout mice. J Psychopharmacol (2009) 0.81
Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): evaluation in vitro and in vivo. Endocrinology (1998) 1.10
Prescribing information in 26 countries: a comparative study. Eur J Clin Pharmacol (2003) 0.93
Behavioural effects of pinoline in the rat forced swimming, open field and elevated plus-maze tests. Pharmacol Res (1997) 0.90
Drug use in Estonia in 1994-1995: a follow-up from 1989 and comparison with two Nordic countries. Eur J Clin Pharmacol (1998) 0.90
Behavioral differences in an elevated plus-maze: correlation between anxiety and decreased number of GABA and benzodiazepine receptors in mouse cerebral cortex. Naunyn Schmiedebergs Arch Pharmacol (1988) 0.87
Anorexigenic cocaine- and amphetamine-regulated transcript peptide intensifies fear reactions in rats. Brain Res (2000) 0.87
Evidence for involvement of the melanocortin MC4 receptor in the effects of leptin on food intake and body weight. Eur J Pharmacol (1998) 0.85
Selective antagonist for the melanocortin 4 receptor (HS014) increases food intake in free-feeding rats. Biochem Biophys Res Commun (1998) 0.85
Differential effects of melanocortin peptides on ingestive behaviour in rats: evidence against the involvement of MC(3) receptor in the regulation of food intake. Neurosci Lett (2000) 0.84
Putamen mitochondrial energy metabolism is highly correlated to emotional and intellectual impairment in schizophrenics. Neuropsychopharmacology (2000) 0.84
The effects of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in rat. Neuropharmacology (1997) 0.84
Rats with high or low sociability are differently affected by chronic variable stress. Neuroscience (2008) 0.84
Orexigenic effect of the melanocortin MC4 receptor antagonist HS014 is inhibited only partially by neuropeptide Y Y1 receptor selective antagonists. Can J Physiol Pharmacol (2000) 0.84
Levels of transcription factors AP-2alpha and AP-2beta in the brainstem are correlated to monoamine turnover in the rat forebrain. Neurosci Lett (2001) 0.83
Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse. Psychopharmacology (Berl) (1991) 0.83
Comparison of the antioxidant activity of melatonin and pinoline in vitro. J Pineal Res (1998) 0.83
Long-term administration of MC4 receptor antagonist HS014 causes hyperphagia and obesity in rats. Neuroreport (1999) 0.82
Overflow of noradrenaline and dopamine in frontal cortex after [N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine] (DSP-4) treatment: in vivo microdialysis study in anaesthetized rats. Naunyn Schmiedebergs Arch Pharmacol (1997) 0.81
High prevalence of coeliac disease: need for increasing awareness among physicians. Dig Liver Dis (2006) 0.81
Anxiolytic-like effect of neuropeptide Y (NPY) and NPY13-36 microinjected into vicinity of locus coeruleus in rats. Brain Res (1998) 0.81
Characterization of rat exploratory behavior using the exploration box test. Methods Find Exp Clin Pharmacol (1997) 0.80
Neuropeptide Y attenuates the effect of locus coeruleus denervation by DSP-4 treatment on social behaviour in the rat. Neuropeptides (2000) 0.80
Alpha-helical CRF(9-41) prevents anxiogenic-like effect of NPY Y1 receptor antagonist BIBP3226 in rats. Neuroreport (1997) 0.79
Inhibition of amphetamine- and apomorphine-induced behavioural effects by neuropeptide Y Y(1) receptor antagonist BIBO 3304. Neuropharmacology (2000) 0.79
Effect of chronic stress on behavior and cerebral oxidative metabolism in rats with high or low positive affect. Neuroscience (2009) 0.79
Neuropeptide Y Y1 receptor antagonist BIBP3226 produces conditioned place aversion in rats. Prog Neuropsychopharmacol Biol Psychiatry (1999) 0.79
Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats. Naunyn Schmiedebergs Arch Pharmacol (1994) 0.79
Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226. Br J Pharmacol (1998) 0.79
Access to essential medicines for children: the world health organization's global response. Clin Pharmacol Ther (2007) 0.79
Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population. Pharmacol Toxicol (1996) 0.79
Subdiaphragmatic vagotomy does not prevent the anti-exploratory effect of caerulein in the elevated plus-maze. Neuropeptides (1994) 0.78
Anxiolytic-like effect of the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA) on rat exploratory activity. Pharmacol Biochem Behav (1994) 0.78
The effect of the NMDA receptor antagonist dizocilpine on behavioral manifestations of serotonin and adrenergic antidepressants in rats. Methods Find Exp Clin Pharmacol (2010) 0.78
Environment and the serotonergic system. Eur Psychiatry (2010) 0.78
Human adrenergic alpha 2A receptor C-1291G polymorphism leads to higher consumption of sweet food products. Mol Psychiatry (2007) 0.78
Cholecystokinin in CSF from depressed patients: possible relations to severity of depression and suicidal behaviour. Eur Neuropsychopharmacol (1998) 0.78
Evidence that orexigenic effects of melanocortin 4 receptor antagonist HS014 are mediated by neuropeptide Y. Biochem Biophys Res Commun (1998) 0.78
Platelet monoamine oxidase in healthy 9- and 15-years old children: the effect of gender, smoking and puberty. Prog Neuropsychopharmacol Biol Psychiatry (2001) 0.78
Effects of low dose N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine administration on exploratory and amphetamine-induced behavior and dopamine D2 receptor function in rats with high or low exploratory activity. Neuroscience (2005) 0.77
Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze. Neuropharmacology (1994) 0.77
Peripheral benzodiazepine binding sites. Pharmacol Ther (1989) 0.77
Central- and peripheral-type benzodiazepine receptors: similar regulation by stress and GABA receptor agonists. Pharmacol Biochem Behav (1989) 0.77
Role of N-methyl-D-aspartic acid and cholecystokinin receptors in apomorphine-induced aggressive behaviour in rats. Naunyn Schmiedebergs Arch Pharmacol (1995) 0.77
Cholecystokinin peptides and receptor binding in Alzheimer's disease. J Neural Transm (Vienna) (1996) 0.77
Correlation between exploratory activity in an elevated plus-maze and number of central and peripheral benzodiazepine binding sites. Naunyn Schmiedebergs Arch Pharmacol (1991) 0.77
Social isolation of rats increases the density of cholecystokinin receptors in the frontal cortex and abolishes the anti-exploratory effect of caerulein. Naunyn Schmiedebergs Arch Pharmacol (1993) 0.77
Insulin sensitivity at childhood predicts changes in total and central adiposity over a 6-year period. Int J Obes (Lond) (2011) 0.77
Anxiogenic-like effect of the NPY Y1 receptor antagonist BIBP3226 administered into the dorsal periaqueductal gray matter in rats. Regul Pept (1998) 0.77
Different molecular forms of cholecystokinin and CCKB receptor binding in the rat brain after chronic antidepressant treatment. Naunyn Schmiedebergs Arch Pharmacol (1997) 0.77
NPY Y1 receptors in the dorsal periaqueductal gray matter regulate anxiety in the social interaction test. Neuroreport (1998) 0.77
The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. Biol Psychiatry (1997) 0.77
Differential effects of beta-carbolines and antidepressants on rat exploratory activity in the elevated zero-maze. Pharmacol Biochem Behav (2000) 0.77
The effects of cholecystokinin A and B receptor antagonists, devazepide and L 365260, on citalopram-induced decrease of exploratory behaviour in rat. J Physiol Pharmacol (1996) 0.76
NewMood: a productive European model of collaboration for translational research in depression. Eur Neuropsychopharmacol (2010) 0.76
The effect of serotonin transporter gene promoter polymorphism on adolescent and adult ADHD symptoms and educational attainment: a longitudinal study. Eur Psychiatry (2012) 0.76
Effects of central and peripheral type benzodiazepine ligands on thyrotropin and prolactin secretion. Neuropeptides (1992) 0.76
Effect of COMT Val158Met polymorphism on personality traits and educational attainment in a longitudinal population representative study. Eur Psychiatry (2013) 0.76
Role of socio-cultural factors on changes in fitness and adiposity in youth: a 6-year follow-up study. Nutr Metab Cardiovasc Dis (2012) 0.76
The effect of drugs acting on CCK receptors and rat free exploration in the exploration box. J Physiol Pharmacol (1997) 0.76
Autoradiographic localization of [3H]-pinoline binding sites in mouse tissues. Methods Find Exp Clin Pharmacol (1997) 0.75
Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia. Eur J Clin Pharmacol (1997) 0.75
Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze. Psychopharmacology (Berl) (1993) 0.75
Cholecystokinin peptides and receptor binding in rat brain after DSP-4 treatment. Neuropeptides (1998) 0.75
Changes at cholecystokinin receptors induced by long-term treatment with diazepam and haloperidol. Eur Neuropsychopharmacol (1992) 0.75
Possible role of cholecystokinin-A receptors in regulation of thyrotropin (TSH) secretion in male rats. Neuropeptides (1992) 0.75
Effects of central and peripheral type benzodiazepine ligands on growth hormone and gonadotropin secretion in male rats. Pharmacol Toxicol (1992) 0.75
Thymopentin antagonizes stress-induced changes of GABA/benzodiazepine receptor complex. Regul Pept (1990) 0.75
Stress-protection action of beta-phenyl(GABA): involvement of central and peripheral type benzodiazepine binding sites. Pharmacol Toxicol (1990) 0.75
Changes in GABA-benzodiazepine receptor complex and in peripheral benzodiazepine receptors in male mice after copulation. Pharmacol Biochem Behav (1995) 0.75
The involvement of sigma and phencyclidine receptors in the action of antipsychotic drugs. Pharmacol Toxicol (1992) 0.75
Role of fluidity of membranes on the guanyl nucleotide-dependent binding of cholecystokinin-8S to rat brain cortical membranes. Biochem Pharmacol (1998) 0.75
Binding of pinoline on the 5-hydroxytryptamine transporter: competitive interaction with [3H] citalopram. Pharmacol Toxicol (1997) 0.75
Anti-exploratory effect of N-methyl-D-aspartate in elevated plus-maze. Involvement of NMDA and CCK receptors. Eur Neuropsychopharmacol (1993) 0.75
Variation in behavioral response to baclofen: correlation with benzodiazepine binding sites in mouse forebrain. Naunyn Schmiedebergs Arch Pharmacol (1986) 0.75
Cholecystokinin receptor binding in morphine analgesia: tolerance, withdrawal and abstinence. Neuropeptides (1994) 0.75
Does biology duplicate itself? Trends Pharmacol Sci (1988) 0.75